StemCyte International (TPE:4178) appointed Lu Kung-Ming as co-chief executive officer on Friday, according to a same-day Taiwan Exchange filing.
Shares of the regenerative therapeutics and cord blood banking company gained over 1% in Monday's late afternoon trade.
Lu joins the company in a newly created co-CEO role and currently serves as chairman of Xin Yao Biotechnology Investment.